Develops next-generation cannabinoid-based therapeutics and formulations for neurological and neurodegenerative disorders—primarily Parkinson's disease—offering pharmacological precision, biomarker-informed product design, and a translational, clinically focused path to market that emphasizes patient-centered outcomes.